翻訳と辞書 |
Tositumomab
Tositumomab was a drug that was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.〔New York Times. July 1, 2003 (Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval )〕 It was sold in the U.S. and Canada under the trade name Bexxar. Sale of the drug was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.〔Notice by the Food and Drug Administration on October 23, 2013. (GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR )〕 This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.〔Carla Mozee for MarketWatch. April 29, 2005 (Glaxo to acquire Corixa for $300 million )〕 ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Tositumomab」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|